Workshop:Progress and Advances in Preclinical immuno-Oncology Research


The rise of cancer immunotherapy such as immune checkpoint modulators, bispecific antibodies, T cell therapy and personalized cancer vaccines instigated a wide range of unique preclinical and translational challenges. The demand for preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immune-oncology. SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.


Final Agenda

1:00-4:35pm BJT

December 17, 2020

Bibo hall, Parkyard Hotel

699 Bibo Road, Zhang Jiang High Tech Park Pudong, Shanghai


Time

Topic

Speaker(s) and Affiliation

1:00–1:30 pm

Registration


1:30–1:40 pm

Opening speech


1:40-2:20 pm

Exploration and Development of Next Generation Tumor Immunotherapy Antibody

Wenzhi Tian, MD, Chairman & CEO of ImmuneOnco Biopharma Co., Ltd

2:20-3:00 pm

Animal modeling for immuno-oncology drug discovery

Davy Ouyang, Vice President of Scientific Research & Innovation at Crown Bioscience Inc

3:00-3:15 pm

Coffee break


3:15-3:55 pm

Immuno-Oncology Therapies & Humanized Animal Models

Jia Zeng, R & D Project Leader of  ALLCELLS

3:55-4:35 pm

Genetically engineered mouse models in oncology research and cancer medicine

Haiyan Zhu, Director of Industrial Customer Department at Shanghai Model Organisms Center, Inc.

 



You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more